Loading
A phase 1 trial of GKL-006 Injection run by Beijing Gene Key Life Technology Co., Ltd, completed.
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular Carcinoma is a phase 1 interventional study registered as NCT07845266 by Beijing Gene Key Life Technology Co., Ltd, with 13 participants enrolled, started 2024-04-16. Conditions recorded: Hepatocellular Carcinoma (HCC) and Unresectable Hepatocellular Carcinoma. Interventions recorded: GKL-006 Injection and transarterial chemoembolization.
Shares Beijing Gene Key Life Technology, GKL-006 Injection, Hepatocellular carcinoma and the tag pipeline.
Shares Beijing Gene Key Life Technology, GKL-006 Injection, Hepatocellular carcinoma and the tag pipeline.
Shares Beijing Gene Key Life Technology, GKL-006 Injection and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/